Inj Noradrenaline and Inj Dopamine mode of action and use
norepinephrine AND dopamine
Surviving Sepsis Campaign norepinephrine dopamine vasopressor recommendation
| Infusion range | Predominant receptor effects | Main effect |
|---|---|---|
| Low dose | Dopaminergic D1 receptors | Renal and splanchnic vasodilation |
| Moderate dose | Beta-1 receptors | Increased heart rate, contractility, and cardiac output |
| High dose | Alpha-1 receptors | Vasoconstriction and increased BP |
| Feature | Noradrenaline | Dopamine |
|---|---|---|
| Main receptor action | Alpha-1 > beta-1 | Dose-dependent D1, beta-1, alpha-1 |
| Dominant clinical effect | Vasoconstriction, raises MAP | Raises cardiac output at moderate dose; vasoconstriction at high dose |
| Septic shock | Preferred first-line | Usually avoided if norepinephrine is available |
| Arrhythmia risk | Lower | Higher |
| Useful when | Vasodilatory hypotension | Hypotension with low output and marked bradycardia, selected cases |